Novavax
NYSE
Novavax's latest marketcap:
As of 06/08/2025, Novavax's market capitalization has reached $1.21 B. According to our data, Novavax is the 8370th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.21 B |
| Revenue (ttm) | 1.25 B |
| Net Income (ttm) | 478.7 M |
| Shares Out | 161.97 M |
| EPS (ttm) | 2.97 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/07/2025 |
Novavax's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/08/2025 | $1.21 B | -12.09% |
| 12/31/2024 | $1.29 B | 125.87% |
| 12/29/2023 | $570.2 M | -29.34% |
| 12/30/2022 | $807 M | -92.54% |
| 12/31/2021 | $10.82 B | 52.38% |
| 12/31/2020 | $7.1 B | 6609.55% |
| 12/31/2019 | $105.8 M | -84.98% |
| 12/31/2018 | $704.4 M | 81.13% |
| 12/29/2017 | $388.9 M | 13.78% |
| 12/30/2016 | $341.8 M | -84.9% |
Company Profile
About Novavax, Inc.
Novavax, Inc. is a biotechnology company dedicated to discovering, developing, and commercializing vaccines to protect against serious infectious diseases. Operating in the United States, Europe, and internationally, Novavax leverages innovative technologies to enhance immune responses.
Key Offerings
- Vaccine Platform: Combines a recombinant protein approach, nanoparticle technology, and the patented Matrix-M adjuvant to boost immune response.
- COVID-19 Vaccine (NVX-CoV2373): Marketed under brand names Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adults and adolescents as a primary series and for booster doses.
- Malaria Vaccine (R21/Matrix-M): Currently in development to address global malaria challenges.
Company Background
Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland, and continues to pioneer advancements in vaccine technology.
Frequently Asked Questions
-
What is Novavax's (NVAX) current market cap?As of 06/08/2025, Novavax (including the parent company, if applicable) has an estimated market capitalization of $1.21 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Novavax (NVAX) rank globally by market cap?Novavax global market capitalization ranking is approximately 8370 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.